At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 40 target
Drug / intervention
BL-B01D1 +1 moredrug
Likely dose
Osimertinib Mesylate Tablets 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 and Osimertinib Mesylate Tablets for Non-small Cell Lung Cancer. Currently recruiting, targeting 40 participants across 1 site.
Detailed Summary
This phase II clinical study is a study to explore the efficacy and safety of BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with histologically and/or cytologically confirmed locally advanced or metastatic non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 2Recruiting
20252026
First PostedJul 2024
Enrollment StartJul 2024
TodayJul 2026
Primary CompletionAug 2026
First PostedJul 12, 2024
Enrollment StartJul 31, 2024
Primary CompletionAug 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 2.0 years agoPrimary completion in 1 month
Interventions
BL-B01D1drug
Administration by intravenous infusion for a cycle of 3 weeks.
Osimertinib Mesylate Tabletsdrug
Oral administration, 80mg daily for a cycle of 3 weeks.